Related Experiment Video
Updated: Nov 28, 2025
Physical Isolation of Endospores from Environmental Samples by Targeted Lysis of Vegetative Cells
Published on: January 21, 2016
[Intensive care unit treatment for patients suffering from COVID-19: the Neuchâtel experience]
Moa-Lina Haller1, Marie-Eve Brunner1, Hervé Olivier Zender1,2
1Service des soins intensifs, Département de médecine, Réseau hospitalier neuchâtelois - Pourtalès, 2000 Neuchâtel.
Abstract:
SARS-CoV-2 appeared in Switzerland in February 2020 and reached Neuchâtel in March. During 2 months, 43 patients were admitted in the intensive care unit. 55% of ICU admitted patients received mechanical ventilation, 66% of which in prone position. All patients were treated with hydroxychloroquine. The majority of patients received antiretrovirals. One patient was treated with remdesivir. Near half the patients were treated with tocilizumab. One patient received a convalescent plasma obtained from patients who had recovered from COVID-19. The mortality rate was 17%. These results are in line with those from university intensive care units in Switzerland.
